R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

From high-profile resignations to the addition of seasoned executives and scientific leaders, last month saw a series of notable changes.

R&D

deVere and Inventus comment on the UK Autumn Budget and what it means for life sciences in the country.

R&D

Phil Davey is the General Manager at Alnylam for the UK, Ireland, the Nordics, and Canada.

R&D

Global pharmaceutical market projections through 2030, with Norstella's Daniel Chancellor.

R&D

From high-profile resignations to strategic appointments, October was a buzzy month for pharma industry personnel news.

R&D

Researchers are beginning to imagine a future in which development pipelines are more predictive, more efficient, and ultimately more humane.